US equities |
MU $855.10 ▲+0.00% SPCX $141.31 ▲+0.00% TSLA $398.50 ▲+0.00% SNDK $1,126.52 ▲+0.00% AMD $483.90 ▲+0.00% NVDA $206.69 ▲+0.00% AMZN $250.69 ▲+0.00% INTC $60.55 ▲+0.00%
FinancialContent

Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (NQ:KNSA)

93.29 UNCHANGED
Delayed Quote Updated: 4:00 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Clears the Minervini Trend Template but Awaits a Lower-Risk Entry ↗
Via Chartmill
News headline image
Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors ↗
Profit growth is outpacing revenue gains, giving the company firepower to advance pipeline candidates without diluting shareholders. 
Via The Motley Fool
Topics Artificial Intelligence Earnings
News headline image
Kiniksa (KNSA) Q3 2026 Earnings Call Transcript ↗
ARCALYST revenue surged 58% year-over-year as the company raised full-year guidance. 
Via The Motley Fool
Topics Earnings
News headline image
What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call ↗
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) raised its full-year 2026 revenue guidance after reporting third-quarter ARCALYST revenue growth of 58% year over year, as the company continued to... 
Via MarketBeat
Topics Earnings
Kiniksa Pharmaceuticals (NASDAQ:KNSA): High Growth Momentum Meets a Breakout Setup ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Pairs Strong Growth With a High-Quality Technical Setup ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA): Affordable Growth Backed by Accelerating Earnings ↗
Via Chartmill
Gap-Up and Gap-Down Stocks in Today's Session ↗
Via Chartmill
Premarket Movers: Gainers and Losers Ahead of Today's US Open ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Pairs High Growth Momentum With a Breakout Setup ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Meets Minervini Trend Template and High-Growth Momentum Criteria ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Combines Strong Growth With a High-Quality Technical Setup ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Combines High Growth Momentum with a Breakout Setup ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shows Strong Growth and a Technical Setup for a Potential Breakout ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA): A Compelling Affordable Growth Story ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Growth Stock Surges on Revenue Beat and Raised Guidance ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA): A High-Growth Stock with Strong Technical Setup ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA): A High Growth Momentum Stock With a Breakout Setup ↗
Via Chartmill
News headline image
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3 ↗
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) said its commercialized recurrent pericarditis treatment ARCALYST continues to grow, while the company has begun a pivotal Phase 3 study of follow-on... 
Via MarketBeat
Which stocks are gapping on Tuesday? ↗
Via Chartmill
News headline image
Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights ↗
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) reported second-quarter ARCALYST revenue of $243.6 million, up 55% from a year earlier and more than $29 million from the first quarter, as the... 
Via MarketBeat
Topics Artificial Intelligence Earnings
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Qualifies as an Affordable Growth Stock With Strong Revenue and Earnings Momentum ↗
Via Chartmill
Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA) Presents a Compelling GARP Opportunity ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Screens as Affordable Growth ↗
Via Chartmill
Kiniksa Pharmaceuticals (KNSA) Shows Explosive Potential with Perfect Minervini Trend Template and 460% EPS Growth ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Surges on Q1 Earnings Beat and Raised ARCALYST Guidance ↗
Via Chartmill
Topics Earnings
News headline image
Kiniksa (KNSA) Q1 2026 Earnings Transcript ↗
Kiniksa (KNSA) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally ↗
Kiniksa Pharmaceuticals is gaining momentum after strong ARCALYST sales growth, raised revenue guidance, and optimism surrounding its next-generation pipeline 
Via MarketBeat
News headline image
Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today ↗
The biotech delivered a beat-and-raise first quarter. 
Via The Motley Fool
Gapping stocks in Tuesday's session ↗
Via Chartmill
< Previous 1 2 3 4 5 6 Next >